Expanding Phase III Study of Tyroserleutide for Injection

Inclusion Criteria: * Signed informed consent * Aged ≥ 18 years and ≤ 75 years old, male or female * Subject underwent resection of hepatocellular carcinoma (confirmed by pathology) * The tumor characteristics must meet the following:A single tumor with a maximum diameter \>5cm ,Preoperative imaging, or Intraoperative visual observation.; Exclusion Criteria: * Concomitant malignant tumor(s) in other systems is/are present * Tumor thrombosis in the branch of portal vein or in hepatic vein is detected by preoperative imaging or observed during the surgery * The subject received any previous systemic anti-HCC therapy prior to the resection surgery (except the resection surgery), such as liver transplantation, intervention, ablation, radiotherapy, chemotherapy, molecular targeted therapy or other anti-HCC therapy * The subject took Sorafenib prior to randomization * The subject took other study/investigational drugs 7 days prior to randomization * The subject took Kang Laike injection/soft capsule，or Jinke Huaier granule 7 days prior to randomization * The subject has central nervous system disease, mental illness, unstable angina, congestive heart failure, severe arrhythmia or other severe uncontrolled diseases * The subject has history of investigational drug or similar drug allergy * The baseline examination indicates that infection, bleeding, bile leakage, or other postoperative complications are present * The subject is pregnant, lactating, or urine pregnancy test result is positive * Baseline (post-resection) examination exist tumor recurrence or metastasis;